Navigation
Life Science Cluster für Hamburg und Schleswig-Holstein

News

Your contact person

Manager PR & Communications Jan Phillip Denkers

Filter reset
Evotec has started the search for a permanent solution for the position of CEO.

Evotec announces CEO transition

Evotec SE announced that after close to 15 years of successful service, CEO Dr Werner Lanthaler has informed the company, that he will not continue ...

Read more …
Hamburg's Senator for Economics and Innovation, Dr. Melanie Leonhard, met Dr. Werner Lanthaler, Evotec CEO (left), and Dirk Winkler, SVP Hit Identification, Global Drug Discovery Services at Evotec (right), during her visit to the Manfred Eigen campus.
Hamburg's Senator for Economics and Innovation, Dr. Melanie Leonhard, met Dr. Werner Lanthaler, Evotec CEO (left), and Dirk Winkler, SVP Hit Identification, Global Drug Discovery Services at Evotec (right), during her visit to the Manfred Eigen campus. ( Picture: © Nico Michaelsen, Evotec SE)

Senator Dr. Melanie Leonhard visits Evotec

Evotec SE announced that new high-throughput screening (“HTS”) facilities at the Company’s headquarters in Hamburg, as well as additional equipment for investigating ...

Read more …
For academic research, MHH will receive access to the data generated within the partnership by working with Evotec’s AI-driven analytics software PanHunter. (Picture: © Evotec)

Evotec enters partnership with Hannover Medical School

Evotec SE announced that the Company has entered a partnership with Hannover Medical School (“MHH”), one of the leading German universities, to ...

Read more …
Preview of the new biologics manufacturing plant J.POD® Toulouse, France (EU); (Image: © Brunerie & Irissou Architectes, Thomas Brunerie)

Evotec initiates ground-breaking for new biologics facility

Evotec SE today officially launched the construction of its J.POD® biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® Toulouse, ...

Read more …
Aurobac will work to shift the strategy related to antibiotic treatment regimens, which at the moment leans heavily on empirical approaches using broad-spectrum and unfocused medicines. (Picture: © stock.adobe.com/Christoph Burgstedt)

Evotec, Boehringer Ingel­heim and bioMérieux cooperate

Evotec SE, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a ...

Read more …

Evotec: strategic roadmap towards precision medicine

Evotec SE presents at its virtual Capital Markets Day how artificial intelligence (“AI”) and machine learning (“ML”) enabled precision technologies in discovery ...

Read more …
The molecule has shown great potential to produce a powerful antiviral response against infections with SARS-CoV-2. (Picture: ©NicoElNino/adobe.stock.com)

Evotec: € 7.5 m grant for development of COVID-19 therapeutic

Evotec SE announced that the Company has been selected by the German Federal Ministry of Education and Research (“BMBF”) to receive a grant for the ...

Read more …
Evotec is excited to provide a new compound that has the potential to improve the lives of many women

Evotec receives US$ 18 m grant for women's health

Evotec SE announced that the Company has received a US$ 18 m grant from the Bill & ...

Read more …

Evotec Initiates US IPO

Evotec expects to grant the underwriters a 30-day option to purchase up to an additional 3,300,000 ADSs. The sale of the ADSs and the issuance ...

Read more …

Evotec: Collaboration with Bristol Myers Squibb

Evotec SE announced that its collaboration with Bristol Myers Squibb has been expanded to include a new cell type, triggering a payment of $ 9.0 ...

Read more …
The facility employs J.POD® technology that uses autonomous clean rooms to run small, highly intensified production processes, thereby reducing the cost of biologics manufacturing. (Picture: ©Benjamin Benschneider)

Just - Evotec Biologics opens J.POD® 1 US

Evotec SE announced the opening of the company’s late-stage clinical and commercial biologics cGMP manufacturing facility (J.POD® 1 US) in Redmond, Washington. ...

Read more …
Evotec creates further opportunities for long-term growth with "Campus Levi-Montalcini" in Verona. (Picture: ©Z S / Unsplash)

Evotec creates long-term growth opportunities

Evotec SE announced that Evotec has added significant opportunities for further, long-term growth by acquiring the Verona site from GlaxoSmithKline SpA (“GSK”). ...

Read more …
Job board